Apeloa Pharmaceutical's (SHE:000739) unit, Zhejiang Apeloa Kangyu Pharmaceutical, received a certificate of suitability from the European Union for its amantadine hydrochloride, according to a Shenzhen bourse filing on Friday.
The drug is used to treat symptoms caused by influenza A virus infection, as well as Parkinson's Disease.